Quantcast

Latest Retinoids Stories

2010-02-23 05:30:00

HAYWARD, Calif., Feb. 23 /PRNewswire-FirstCall/ -- Solta Medical, Inc. (Nasdaq: SLTM), a global leader in the medical aesthetics market, today announced it has entered into a definitive agreement to acquire privately-held Aesthera Corporation, which is based in Pleasanton, California. Under the terms of the definitive agreement, Solta will acquire Aesthera for $5.25 million in Solta common stock and cash, with potential additional base line milestones of $750,000 for a consideration of...

2010-02-15 07:00:00

CINCINNATI, Feb. 15 /PRNewswire/ -- Today, the British Journal of Dermatology, one of the world's leading dermatology journals, published a head-to-head anti-aging clinical trial comparing an off the shelf brand to the leading prescription wrinkle regimen, 0.02 percent tretinoin. The study found that the Olay Professional Pro-X regimen clinically improves the appearance of facial lines and wrinkles as well as this gold standard prescription regimen in just 8 weeks.* To view the multimedia...

2009-09-09 08:45:00

NEW YORK, Sept. 9 /PRNewswire/ -- In 2008, the global anti-aging skincare market approached $15 billion(1), with 32 percent of U.S. facial skincare product launches boasting anti-aging claims(2) many over-the-counter products are claiming to achieve comparable benefits as prescription anti-aging treatments. The interest in anti-aging products continues to grow, but FDA-approved prescription products with rigorous efficacy and safety standards are still the preferred option when it comes...

2009-07-15 08:00:00

PLEASANTON, Calif., July 15 /PRNewswire/ -- Roche Holding AG, the world's biggest maker of cancer drugs, recently announced the withdrawal of its Accutane acne medicine from the US Market. The decision was largely driven by falling market share, the product reaching the end of its life cycle, and the high cost of personal injury lawsuits. (i) "While the withdrawal of Accutane comes on the heels of much public scrutiny, the bottom line is that physicians and patients need a viable...

2009-06-26 15:32:00

TRENTON, N.J., June 26 /PRNewswire/ -- Marcus Rayner, executive director of the New Jersey Lawsuit Reform Alliance, a statewide, bipartisan group of individuals, businesses and organizations dedicated to improving the state's civil justice system and advocating for legal reform in the legislature and in the courts, today issued the following statement in reaction to Roche's announcement that the company will immediately discontinue Accutane(R), a treatment for severe acne: "Thanks to an...

2fd3bb543c6dd19dde6f054b1ddcbd4c1
2009-06-26 14:28:34

Roche Holding AG announced on Friday that it is no longer selling its acne drug Accutane amid slowing sales due to the move towards generic alternatives. "As always when you have generics around your market share drops," Roche spokeswoman Martina Rupp told Reuters. "This was an economical decision driven by falling market share," she said. Indeed, Accutane's market share had declined to around 4 to 5 percent. Generics of the potent drug have been available since 2002 and now dominate the...

2009-03-17 11:43:00

Company brings the latest in Italian skin care to the U.S. TURIN, Italy, March 17 /PRNewswire/ -- Direct from Italy, Perlabella PureDose Pearls bring the latest in anti-aging skin care technology to America. The skin care line offers four highly concentrated anti-aging serums: Retinol Face, Q10 Face, Vitamin C Face and Retinol Eye. "Perlabella PureDose Pearls are unique because they are airtight, making it impossible for water, air or preservatives to compromise the integrity of their...

2009-03-06 17:59:00

SAN DIEGO, March 6 /PRNewswire/ -- AndroScience Corporation (ASC(TM)), a developmental stage pharmaceutical company announced results of a Phase 2a dose-ranging study of their lead clinical compound for the treatment of acne. The randomized, double-blinded, vehicle-controlled study completed in late 2008 enrolled 186 patients with acne and consisted of twice daily topical applications of ASC-J9(TM) cream for 12 weeks to evaluate safety and ascertain preliminary efficacy. ASC-J9(TM)...

2009-03-06 09:00:00

Expanded Dermatology Division of Valeant Pharmaceuticals Introduces Fixed Combination Acne Treatment Designed to Increase Patient Satisfaction and Use SAN FRANCISCO, March 6 /PRNewswire-FirstCall/ -- Coria Laboratories, the newly expanded dermatology division of Valeant Pharmaceuticals International (NYSE: VRX), announced today the commercial launch of Acanya(TM) Gel (clindamycin phosphate 1.2% and benzoyl peroxide 2.5%) indicated for the once-daily treatment of acne vulgaris in patients 12...

2009-02-26 07:00:00

FORT WORTH, Texas, Feb. 26 /PRNewswire-FirstCall/ -- Coria Laboratories, the newly expanded dermatology division of Valeant Pharmaceuticals International (NYSE: VRX), today announced six data presentations on Acanya Gel at the 67th Annual Meeting of the American Academy of Dermatology (AAD), taking place March 6 - 10, 2009, at the Moscone Center, San Francisco. The presentations demonstrate the efficacy and safety of once daily Acanya Gel (clindamycin phosphate 1.2% and benzoyl peroxide...


Word of the Day
ambsace
  • Bad luck; misfortune.
  • The smallest amount possible or the most worthless thing.
The word 'ambsace' comes from a Latin word meaning 'both'.